Amylyx Overview

  • Founded
  • 2013
  • Status
  • Private
  • Employees
  • 3
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $59.6M
Latest Deal Amount
  • Investors
  • 6

Amylyx General Information


Developer of a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases designed to target the neuroinflammation and nerve cell death that characterize these disorders. The company's therapeutics are a combination of existing compounds that have synergistic effects in preventing nerve cell death and neurotoxic inflammation in multiple preclinical models, enabling patients suffering from Alzheimer's disease and other neuroinflammation diseases to begin treatment more quickly, resulting in a higher likelihood of successful treatment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 43 Thorndike Street
  • Cambridge, MA 02141
  • United States
+1 (617) 000-0000

Amylyx Timeline

Financing RoundFinancing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Amylyx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 01-Jul-2020 $59.6M 000.00 Completed Generating Revenue
4. Debt - PPP 13-Apr-2020 00.00 Completed Startup
3. Early Stage VC (Series A) 22-Aug-2016 000 00.00 0000 Completed Startup
2. Grant 20-Jul-2016 $3.56M $1.3M Completed Startup
1. Early Stage VC $1.3M $1.3M Completed Startup
To view Amylyx’s complete valuation and funding history, request access »

Amylyx Cap Table

Stock # of Shares
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
To view Amylyx’s complete cap table history, request access »

Amylyx Executive Team (8)

Name Title Board Seat Contact Info
Joshua Cohen Co-Founder, Co-Chief Executive Officer & Chairman
Justin Klee Co-Founder, Co-Chief Executive Officer, President & Board Member
Debra Canner Chief Human Resources Officer
Kent Leslie Chief Scientific Officer
Margaret Olinger Chief Commercial Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Amylyx Board Members (10)

Name Representing Role Since
Alan Walts Ph.D Self Board Observer 000 0000
Felix von Coerper ALS Investment Fund Board Member 000 0000
George Milne Amylyx Board Member 000 0000
Isaac Cheng MD Morningside Group Board Member 000 0000
Joshua Cohen Amylyx Co-Founder, Co-Chief Executive Officer & Chairman 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Amylyx Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amylyx Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ALS Investment Fund Venture Capital Minority 000 0000 000000 0
Henri Termeer Angel (individual) Minority 000 0000 000000 0
Morningside Group Venture Capital Minority 000 0000 000000 0
ALS Finding a Cure Foundation Limited Partner Minority 000 0000 000000 0
Cure Alzheimer's Fund Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »